The ideal method to mobilize autologous hematopoietic stem cells (AHSCs) in patients with lymphoma or multiple myeloma remains to be determined. The use of plerixafor, added to growth factor, may overcome the limitations to the use of growth factor mobilization without chemotherapy. We developed and validated a cost-based decisionmaking algorithm that uses the CD34 þ cell count in the peripheral blood on the fourth day of G-CSF administration and the target CD34 þ cell count for the specific patient to decide on the use of plerixafor (MUSC algorithm). We compared this approach (MA cohort) with a historical cohort of patients undergoing mobilization with CY 2000 mg/m 2 followed by G-CSF and GM-CSF (CY cohort). Fifty individuals are included in the MA cohort and 81 in the CY cohort. The mobilization failure rate was 2% in the MA cohort vs 22% in the CY cohort (P ¼ 0.01). Fewer patients in the MA cohort than in the CY cohort had infectious complications during mobilization requiring hospitalization (2 vs 30% Po0.01). There was significant shortening in the median number of days between starting mobilization and undergoing transplantation in the MA cohort (14 vs 43 days, Po0.01). In conclusion, growth factor and patientadapted use of plerixafor provides safer hematopoietic stem cell mobilization and faster access to AHSC transplantation.
Introduction
Autologous, peripheral blood, hematopoietic stem cell (AHSC) transplantation is a pivotal component in the management of younger patients with multiple myeloma (MM) [1] [2] [3] and relapsed or refractory, chemosensitive, Hodgkin's and non-Hodgkin's lymphomas. [4] [5] [6] The best strategy for AHSC mobilization is unknown. Traditionally, mobilization has been performed with the use of chemotherapy agents (particularly CY) combined with growth factors (G-CSF and/or GM-CSF). [7] [8] [9] Yet successful mobilization can also be achieved with the use of growth factors alone, [7] [8] [9] [10] [11] a practice now standard in some large transplant centers. 9 Possible advantages of the use of chemotherapy mobilization are the potential for in vivo purging of residual malignant cells and the higher yield of CD34 þ cells collected. 8, 12 However, the value of in vivo purging has been challenged by the lack of evidence that patients mobilized with chemotherapy agents have superior disease control after transplantation, 13 and lack of correlation between the presence of cancer cells in the apheresis product and risk or timing of relapse after transplant. 14, 15 Mobilization of AHSC with growth factors alone has several potential advantages over the use of CY and growth factors. It potentially shortens the interval between the start of mobilization and transplantation, as this strategy does not cause cytopenias. Growth factor-only mobilization is also associated with lower rate of catheter-associated infection and hospital admission. [7] [8] [9] Nevertheless, growth factor mobilization often fails to yield the desired number of CD34 þ cells, particularly in heavily pretreated patients, 10 ,11 patients exposed to lenalidomide 16, 17 and those with significant BM infiltration by the underlying malignancy. 11, 18 Plerixafor (formerly AMD3100), an inhibitor of SDF 1alpha/CXCR4 binding, 19, 20 is available for concomitant use with G-CSF for AHSC mobilization in patients with MM 21 and non-Hodgkin's lymphoma, 22 improving the yield of CD34 þ collection. Plerixafor along with G-CSF has been shown to successfully mobilize CD34 þ cells in patients either failing or likely to fail standard mobilization with growth factor or growth factor combined with chemotherapy. 23, 24 Plerixafor, however, is expensive and probably dispensable in a large proportion of patients likely to yield an appropriate number of CD34 þ cells with growth factor alone.
We hypothesized that growth factor mobilization, used in the setting of an algorithm that allows 'real-time', individualized use of plerixafor for patients failing to mobilize or for whom the addition of plerixafor is likely to save costs, is more efficient and safer than CY-based mobilization. We addressed our hypothesis by performing a retrospective analysis of two distinct mobilization practices in our transplant center.
Methods

CY mobilization
Mobilization with CY and growth factor was the favored method of AHSC mobilization at our institution until November 2008. A tunneled apheresis catheter was implanted before initiation of mobilization. Patients then received outpatient mobilization with CY at the dose of 2000 mg/m 2 followed by G-CSF 5 mg/kg/day and GM-CSF 5 mg/kg/day, starting the day after CY administration and continuing until hematopoietic stem cell (HSC) collection was completed. Complete blood counts were monitored and, once total WBC count exceeded 1000 per mm 3 , patients underwent daily monitoring of peripheral blood CD34 þ count (PB-CD34 þ ). Daily apheresis sessions typically started once PB-CD34 þ 410 per mm 3 and continued until target for collection was met (T-CD34 þ ). The apheresis equipment used was COBE Spectra, software version 6.1. Each apheresis session consisted in the processing of at least three total blood volumes. Hereafter, the cohort of patients undergoing mobilization as described above will be reported as 'CY' cohort.
MUSC mobilization algorithm
We have developed a cost-based decision-making algorithm to determine whether to add plerixafor to an ongoing G-CSF mobilization of AHSC. The development and validation of this algorithm has been described elsewhere and is beyond the scope of this paper. 25 In brief, the algorithm dictates the use of plerixafor, starting on the fourth day of G-CSF mobilization, depending on PB-CD34 þ and patient-specific T-CD34 þ . Patients received G-CSF (at the dose of 10 mg/kg/day) daily for 4 days. On day 4, a tunneled apheresis catheter was implanted and PB-CD34 þ was checked. If PB-CD34 þ exceeded a certain target-specific threshold (for example, threshold of 14 CD34 þ per mm 3 for T-CD34 þ of 3 Â 10 6 CD34 þ per kg; threshold of 25 CD34 þ per mm 3 for T-CD34 þ of 5 Â 10 6 CD34 þ per kg), apheresis was started immediately and repeated daily until T-CD34 þ was met. In the event of PB-CD34 þ equal or inferior to the target-specific threshold, daily plerixafor (at the dose of 240 mg/kg/day) was started in the evening of the fourth day of G-CSF and apheresis started in the following morning (day 5). Daily G-CSF, apheresis and plerixafor continued daily until target was met, typically 3 Â 10 6 CD34 þ cells per kg (aiming at collection for one transplant procedure) or 6 Â 10 6 CD34 þ cells per kg (for two transplant procedures). Apheresis equipment and procedures were identical to those described above for the CY cohort.
The MUSC mobilization algorithm was developed in January 2009 and became the preferred mobilization strategy at our center. The cohort of patients undergoing mobilization according to the MUSC algorithm will be referred to as 'MA' cohort.
Mobilization costs
We performed an exploratory comparative analysis of estimated average costs associated with each of the mobilization approaches. For this analysis, medication doses were based on a 75 kg individual with a body surface area of 1.9 m 2 , and not the patient actual weight and body surface area, to facilitate calculation. Medication prices were based on the listed average wholesale price for each product. The estimated charges for administration of CY were US$110.20, daily charges for growth factor administration were US$768.90 and for plerixafor administration were US$7812.00. The daily charges associated with apheresis (including physician, facility, equipment and cryopreservation fees) were based on our program's historical charges of US$6922.00 per day of apheresis. Average daily charges for hospitalization for fever and neutropenia were extracted from the literature 26 (corrected for inflation) and estimated at US$2140.84 per day. The cost per successful collection was calculated as the total estimated cost in each cohort divided by the number of successful collections. Only the costs associated with the first mobilization attempt were included. Infusion of cryopreserved HSC was performed on day 0 following institutional guidelines. All patients received G-CSF at the dose of 5 mg/kg/day starting on day 7 and continuing until ANC 4500 per mm 3 . Prophylaxis against opportunistic infections consisted of fluconazole 400 mg/ day, acyclovir 800 mg twice daily and ciprofloxacin 500 mg twice daily. Transplant eligibility criteria and supportive care guidelines followed institutional policies and were consistent during the entire period covered by this study.
Transplant procedures
Statistics
We reported proportions with their respective 95% confidence intervals. Comparisons between proportions were made using the w 2 -test. Continuous numerical variables were described using their median and interquartile range (IQR). Comparisons between continuous variables used the Mann-Whitney U-test. Time from beginning of mobilization until day 0 of transplantation (mobilizationtransplant time, MTT) is reported for each cohort using the Kaplan-Meier method and compared using log-rank analysis. Comparison of MTT between cohorts only included patients intending to pursue transplant shortly after completion of collection, therefore excluding patients whose HSC were stored to provide an autologous transplant as a subsequent line of therapy (collect and store). In all inference analyses, two-sided P-values of o0.05 were considered to indicate statistical significance. Table 1 . Cohorts MA and CY had similar characteristics, except for a lower proportion of patients with lymphoma (36 vs 59%, P ¼ 0.01) and higher proportion of patients with MM previously treated with lenalidomide (59 vs 21%, P ¼ 0.02) in the MA cohort.
Results
Characteristics of patients
Overall 50 individuals (16 mobilized with G-CSF and 33 requiring G-CSF and plerixafor, 1 failure to complete mobilization) are included in the MA cohort and 81 in the CY cohort. Patients in the CY cohort underwent mobilization between March 2004 and November 2008, whereas patients in the MA cohort underwent mobilization between November 2008 and April 2010. Characteristics of the patients are displayed in
Effectiveness of mobilization
All but 1 patient in the MA cohort (98%, 95% CI 94.1-100%) successfully completed mobilization and stem cell collection, whereas only 63 (77.8%, 95% CI 68.7-86.8%) did so in the CY cohort (Po0.01). Two patients in the MA cohort and 1 in the CY cohort failed to yield the desired minimum of 3 Â 10 6 CD34 þ cells per kg but still proceeded to transplant without a second mobilization attempt. The single patient not completing mobilization in the MA cohort had the mobilization course interrupted because of a soft tissue infection and neutropenia. A second mobilization course is planned. Of the 18 patients who failed mobilization in the CY cohort, 10 completed collection in a subsequent mobilization attempt and 8 failed a second mobilization attempt and could not undergo AHSC transplantation.
Patients completing collection had a median of 1 day of apheresis (IQR 1-2) for both approaches, as displayed in Figure 1 . The median yield of CD34 þ cells per kg was 7 Â 10 6 (IQR 4.2-9.9) in the MA cohort vs 7.74 Â 10 6 (IQR 5-12.7) in the CY cohort (P ¼ 0.08).
Safety of mobilization and timing of HSC transplantation Only 1 patient (2%, 95% CI 0-5.9%) in the MA cohort and 24 (30%, 95% CI 19.7-39.6%) in the CY cohort had complications requiring hospitalization during mobilization (Po0.01), lasting on average 4.1 days per episode. Twenty-one (26%, 95% CI 16.4-35.5%) patients in the CY cohort had fever and neutropenia requiring i.v. antibiotics and 5 (6.2%, 95% CI 0.9-11.4%) had bacteremia.
For the 42 patients in the MA cohort and 77 in the CY cohort who were intended to receive a first autologous transplant upon completion of collection (as opposed to Figure 1 Distribution of number of apheresis day required to meet collection target in each cohort. Note that because there were patients in both cohorts who did not meet the collection target or did not start apheresis, the totals do not equal 100%. 
Cost of mobilization
The estimated average cost of mobilization per patient was US$23 415.71 in the MA cohort and US$22 884.79 in the CY cohort. However, because a higher proportion of patients in the CY cohort failed the initial mobilization attempt, the estimated average cost per patient successfully completing mobilization was lower in the MA cohort (US$23 893.28) than in the CY cohort (US$29 423.31). This cost difference would be certainly higher if the costs associated with subsequent mobilization attempts were included.
Engraftment
Engraftment data are reported for the 59 patients in the CY cohort and 39 in the MA cohort who were able to provide HSC on the first attempt, proceeded to receive a first transplant and have at least 20 days of post transplant follow-up at the time of this report. Neutrophil engraftment (ANC 4500 per mm 2 for 3 consecutive days) occurred after a median of 13 days in the MA cohort and 12 days in the CY cohort (Po0.01). Time to platelet engraftment, defined as the first of 3 consecutive days with plt count 420 000 per mm 2 without platelet transfusion, was not different between the cohorts, with a median of 12 days for the CY cohort and 13 days for the MA cohort (P ¼ 0.2) (Figure 3 ).
Discussion
A combination of CY and growth factors remains the standard HSC mobilization strategy in many transplant centers. This strategy is associated with better CD34 þ cell yield and fewer days of apheresis 9, 10 when compared with the use of growth factors alone. More recently, CY mobilization has been shown to overcome the difficulty in collecting HSC in MM patients previously treated with lenalidomide. 16, 17, 27 The use of plerixafor combined with G-CSF has the potential to overcome the claimed disadvantages of growth factor-only mobilization and to spare patients from the toxicity associated with CY mobilization. Our group has recently developed an algorithm for same day decision on the use of plerixafor based on T-CD34 þ and PB-CD34 þ on the fourth day of mobilization. 25 This algorithm may offset the excessive cost associated with multiple days of apheresis when growth factor only is used and with the unnecessary use of plerixafor in patients for whom G-CSF mobilization alone would suffice. This work shows that the MA approach is also similar to the CY approach in terms of number of apheresis days required and kinetics of engraftment, but superior to the CY approach in terms of rate of mobilization failure, MTT and safety of the mobilization process.
Even though this is not a formal cost analysis, estimated costs in the CY cohort were superior to costs in the MA cohort, if calculated per patient successfully completing collection. Even though the majority of patients in the MA cohort required the use of plerixafor, these additional costs are offset in the CY cohort by the cost of CY, the longer courses of growth factors and frequent hospitalizations due to infections during the neutropenic phase after mobilization. It is also important to emphasize that the CY approach had 22% of mobilization failures, projecting an even higher cost due to the need for another mobilization cycle. Of interest, another group has recently compared the costs between plerixafor along with G-CSF and CY along with G-CSF collection finding similar costs, but more predictable collection results and less hospitalization with the plerixafor strategy. 28 In our analysis, the MA approach was not only more efficient, but it was also safer than the CY approach. Only 1 of the patients in the MA cohort required admission due to toxicity of the mobilization, whereas 24 of the patients in the CY cohort required hospitalization lasting on average 4.1 days.
When compared to the Cy approach, the MA approach offers several practical and logistical advantages. First, there was a dramatic difference in MTT between the two cohorts. For the patient, this translates as less time spent in the transplant center and, for those who have to temporarily relocate to the surroundings of the transplant center, less time away from home. Second, the shorter duration of the implanted tunneled catheter potentially reduces the risk of infection and thrombotic events. Further, the high predictability of the MA strategy allows better use of resources, including personnel, transplant unit beds and apheresis facilities and prevents the need for weekend apheresis. Yet more importantly, all patients in the MA cohort successfully completed collection, whereas 8 of the 18 mobilization failures in the CY cohort never yielded enough CD34 þ cells for a transplant (even in subsequent attempts) and were therefore deprived of a treatment with potential to extend their survival or, in the case of lymphomas, increase their likelihood of cure. Of interest, we found minimal differences in engraftment time between the CY and the MA cohort. Recent analysis of HSC mobilization for autologous transplantation in MM performed by the Mayo Clinic group showed delayed engraftment in patients mobilized with CY along with growth factor, implicating potential detrimental effects of CY in the BM microenvironment. 9 We have not been able to confirm such an effect, perhaps because of smaller sample size or more heterogenous population.
This work has a few important limitations. Due to the heterogeneity of the cohorts, relatively small sample sizes and short follow-up of the MA cohort, we were unable to compare disease-specific outcomes such as OS and PFS after the transplant. Nonetheless, other groups have shown the lack of impact of CY mobilization in the response rate and risk of progression after transplant, questioning the possible benefit of in vivo purging with CY in the control of the underlying malignancy. 9, 13 In summary, the use of the MUSC algorithm, but also similar algorithms developed in other transplant centers, adapted to the local resources and costs, is likely to negate the alleged benefits of chemotherapy mobilization and provide a safer and more efficient mobilization strategy. Definitive comparison between these two strategies can only be accomplished by a prospective multi-institutional randomized trial.
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